1. Clinical & Scientific Overview
Sildenafil Citrate & Tadalafil (PDE-5 Inhibitors — ED & PAH) (TIP-MED-000244, Reference Code [12.12]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Selective Phosphodiesterase Type-5 (PDE5) Inhibitor (Pulmonary Vasodilator & Erectile Dysfunction Agent).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.12], p. 160): Penegra, Manforce, Caverta, Assurans (PAH 20 mg), Revatio — Strengths & Dosage Forms: Tablet: 20 mg (PAH), 25 mg, 50 mg, 100 mg (ED); Injection (PAH): 10 mg/12.5 mL.
Tablet: 20 mg (PAH), 25 mg, 50 mg, 100 mg (ED); Injection (PAH): 10 mg/12.5 mL.
3. Mechanism of Action & Pharmacodynamics
Inhibits cGMP-specific PDE5 in pulmonary vascular smooth muscle and corpus cavernosum -> prevents degradation of nitric oxide-generated cGMP -> smooth muscle relaxation and vasodilation.
4. Therapeutic Indications & Evidence-Supported Uses
- Pulmonary arterial hypertension (PAH—WHO Group 1, 20 mg TDS)
- erectile dysfunction (ED)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Pulmonary Arterial Hypertension: 20 mg PO TDS (q8h). Erectile Dysfunction: 50 mg PO ~1 hour before sexual activity (range 25-100 mg; max once daily; Elderly/CKD/Cirrhosis: start 25 mg). • Paediatric: Pediatric PAH (>=1 yr): Weight-guided specialist dosing (5-10 mg TDS); avoid high doses.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Severe CKD (eGFR <30 mL/min): Start at 25 mg (ED) or reduce PAH frequency to BD if poorly tolerated. • Hepatic: Cirrhosis (Child-Pugh A/B): Start at 25 mg. Severe hepatic failure: Avoid.
Renal: Severe CKD (eGFR <30 mL/min): Start at 25 mg (ED) or reduce PAH frequency to BD if poorly tolerated. • Hepatic: Cirrhosis (Child-Pugh A/B): Start at 25 mg. Severe hepatic failure: Avoid.
Renal: Severe CKD (eGFR <30 mL/min): Start at 25 mg (ED) or reduce PAH frequency to BD if poorly tolerated. • Hepatic: Cirrhosis (Child-Pugh A/B): Start at 25 mg. Severe hepatic failure: Avoid.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: ABSOLUTE CONTRAINDICATION: Any form of organic nitrate (Nitroglycerin, Isosorbide dinitrate, Isosorbide mononitrate), Nicorandil, or Guanylate Cyclase Stimulators (Riociguat) -> catastrophic refractory hypotension and death. Recent MI/stroke (<90 days), severe hypotension (<90/50 mmHg), hereditary retinal dystrophy. • Precautions: Maintain at least 24 hours gap after Sildenafil (48 hours after Tadalafil) before administering nitrates in acute coronary syndrome; separate from alpha-blockers by >=4 hours.
Key Clinical Precautions: Renal: Severe CKD (eGFR <30 mL/min): Start at 25 mg (ED) or reduce PAH frequency to BD if poorly tolerated. • Hepatic: Cirrhosis (Child-Pugh A/B): Start at 25 mg. Severe hepatic failure: Avoid.
8. Adverse Effects Profile
- Headache, facial flushing, dyspepsia, nasal congestion, transient blue-green colour vision tint (PDE6 inhibition).
- Priapism (erection >4 hours—urological emergency), sudden non-arteritic anterior ischaemic optic neuropathy (NAION vision loss), sudden sensorineural hearing loss.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Nitrates / Nicorandil / Riociguat -> fatal hypotension (CONTRAINDICATED); Strong CYP3A4 inhibitors (Ritonavir, Itraconazole, Clarithromycin) -> massive increase in sildenafil levels (avoid in PAH; max 25 mg q48h in ED); Alpha-blockers (Tamsulosin, Prazosin) -> symptomatic postural hypotension
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: NEVER take with nitrate chest-pain tablets or sprays (Sorbitrate, Monotrate, Nitrocontin, Nikoran); seek emergency medical care immediately for sudden vision loss, hearing loss, or erection lasting >4 hours.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 20 mg (PAH), 25 mg, 50 mg, 100 mg (ED); Injection (PAH): 10 mg/12.5 mL.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.12] (p. 160)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.8] Silodosin (Uroselective Alpha-1A Blocker for BPH) — Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist
- [12.9] Dutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor) — Dual Type-1 and Type-2 5-Alpha-Reductase Inhibitor
- [12.10] Tolterodine Tartrate, Oxybutynin Chloride & Flavoxate — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.11] Potassium Magnesium Citrate & Disodium Hydrogen Citrate — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors